生命科学资讯
生物技术与制药领域的最新动态
Thermo Fisher trims Massachusetts headcount with Franklin site closure
GSK plans to lay off up to 350 R&D workers across US, UK
早期投资者Santé Ventures筹集3.3亿美元，布局生物科技、医疗科技与数字健康领域。
Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health
罗氏重返RNA领域，以17亿美元收购赛诺基因项目。
Roche's return to RNA continues with $1.7B deal for Sanegene program
Optellum获英国国民医疗服务体系青睐，参与AI肺癌诊断项目。
Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative
中国新索拉以1.35亿美元购得vTv炎症药物剩余权益。
China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug
第一三共暂停内部开发新一代ADC，关键Datroway数据再次延迟公布。
Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again
赛诺菲GCS抑制剂在法布里病三期试验中受挫，却在戈谢病治疗中取得突破。
Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
阿斯利康研究发现，22个基因与EB病毒感染后慢性疾病风险相关。
AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection
CRO公司Sygnature Discovery计划裁减60名英国员工
CRO Sygnature Discovery plans to send 60 UK staffers packing
Corcept提交主要资产申请批准，尽管FDA已警示存在“重大审查问题”风险。
Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’
卡迪夫高层人事大洗牌，加速推进癌症候选药物研发。
Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate
安进终止与协和发酵麒麟合作，在完成大规模关键试验后退出4亿美元自身免疫疾病协议。
Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
中外制药放弃唯一AI辅助抗体研发项目，但仍对技术前景寄予厚望。
Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
Moderna最新任首席营销官上任不足一年即离职。
Moderna's latest CMO steps down after barely a year
Moderna以5000万美元预付款将晚期罕见病药物转让给Recordati。
Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
阿斯利康以185亿美元重返中国石药集团达成肥胖症药物交易。
AstraZeneca returns to China's CSPC for $18.5B obesity deal
Formation Bio继续在华大举收购，斥资5亿美元达成自身免疫性疾病生物技术协议。
Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
罗氏诊断业务在2025年微增2%，中国市场逆风冲击亚太区销售。
Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales